SEC Form 4 · accession 0001179110-15-015444
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Francis Cogan
Director
Period of report
Nov 24, 2015
Accepted (ET)
Nov 25, 2015 · 2:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 24, 2015 | M | 15,000 | $20.705 | A | 59,309 | D | |
| Common StockF3 | Nov 24, 2015 | S | 15,000 | $105.946 | D | 44,309 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $20.705 | Nov 24, 2015 | M | 15,000 | D | — | May 9, 2017 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2Options are 100% vested on the date of grant.
- F3Sale prices reported for the transactions reported here range from $105.51 to $106.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.